.avif)
Haemonetics Email Format
Medical Equipment Manufacturing
・
1,001-2,500 employees
・
Boston, MA, USA
Haemonetics is a global medical technology company that develops blood management solutions, plasma collection systems, and hospital technologies to improve patient outcomes worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@haemonetics.com
Company Overview
Industry
Medical Equipment Manufacturing
Founded
1971
Headquarters
Boston, MA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Public
Website
Key Executives
Christopher Simon (President and Chief Executive Officer), James C. D'Arecca (Executive Vice President, Chief Financial Officer), Frank W. Chan, Ph.D. (Executive Vice President, Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Haemonetics?
Haemonetics uses the firstinitiallast format, so Jane Smith would be jsmith@haemonetics.com.
What are Haemonetics' three core business segments?
Haemonetics operates across three business segments: Hospital, Plasma, and Blood Center. The Hospital segment includes products like the TEG 6s hemostasis analyzer and the VASCADE vascular closure line, while Plasma and Blood Center focus on collection and processing technologies.
Which hemostasis management products does Haemonetics offer through its Hospital segment?
Haemonetics offers the TEG 6s and TEG 5000 thromboelastography analyzers along with TEG Manager software through its Hospital segment, helping clinicians monitor coagulation and make more informed transfusion decisions at the point of care.
How many employees does Haemonetics have in 2026?
Haemonetics has approximately 2,510 employees globally in 2026. If you need to identify and reach specific contacts at the company, tools like Clay can help you find and verify the right people quickly.
Who leads Haemonetics as its chief executive in 2026?
Christopher Simon serves as President and Chief Executive Officer of Haemonetics in 2026, with James C. D'Arecca as Executive Vice President and Chief Financial Officer and Frank W. Chan, Ph.D. as Executive Vice President and Chief Operating Officer.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating